Recently, we have demonstrated that targeting the proteolytic activity of CTSD using pepstatin-A (Pep-A), a known inhibitor of CTSD, remarkably reduced steatohepatitis in a hyperlipidemic mouse model, thereby pointing towards a role for CTSD activity in NAFLD [19]. The gene discussed is CTSD; the disease is metabolic dysfunction-associated steatotic liver disease.